This approval opens a new, large early-stage bladder cancer market for Imfinzi with no direct immunotherapy competitor in BCG-naïve high-risk NMIBC. Monitor EU/Japan regulatory decisions and physician adoption rates; the VOLGA trial readout last week further strengthens Imfinzi's bladder cancer franchise. Expect modest upward revenue revisions from analysts.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 29 $185.49entry
- T+1 · 6mo ago −3.20%α −3.46% · $179.55
- T+5 · 6mo ago +0.24%α +2.76% · $185.93
- T+20 · 5mo ago +1.58%α +5.21% · $188.41
- T+60 · 3mo ago −10.14%α −11.06% · $166.68
Price Chart
How similar events traded
Executive Summary
AstraZeneca announced FDA approval of Imfinzi (durvalumab) in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), based on the POTOMAC Phase III trial showing a 32% reduction in risk of recurrence, progression, or death. This is the first immunotherapy combination approved in this setting in over 30 years, expanding Imfinzi's label into an early-stage bladder cancer indication with over 31,000 US patients treated annually.
Key Facts
- FDA approved Imfinzi + BCG for BCG-naïve, high-risk NMIBC, the first immunotherapy combination in this setting in over 30 years.
- POTOMAC Phase III trial showed 32% risk reduction (DFS HR 0.68, 95% CI 0.50-0.93, p=0.0154) with median follow-up >5 years.
- Over 31,000 US patients were treated for high-risk NMIBC in 2024; up to 80% of high-risk patients experience recurrence within 5 years.
- Regulatory submissions under review in EU, Japan, and other countries.
- Safety profile consistent with known profiles; no new safety signals; no meaningful impact on quality of life.
Financial Impact
Expands Imfinzi addressable market into early-stage bladder cancer; US high-risk NMIBC population ~31,000 patients annually; first-to-market immunotherapy combination in this setting.
Risk Factors
- Competition from other checkpoint inhibitors or novel agents in NMIBC could emerge.
- Reimbursement and pricing dynamics may limit uptake.
- Long-term OS data not yet mature; DFS benefit may not fully translate to survival advantage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005498 |
| Document: 0001654954-26-005498-index-headers.html | 0001654954-26-005498 |
| Document: 0001654954-26-005498-index.html | 0001654954-26-005498 |
| Document: 0001654954-26-005498.txt | 0001654954-26-005498 |
Track record
77 reports on AZN
18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers